外周血循环肿瘤细胞在前列腺癌诊治中的临床应用价值  

Clinical value of peripheral blood circulating tumor cells in the diagnosis and treatment of prostate cancer

作　　者：赵亚伟[1] 汤磊[1] 李前跃[1] 马旺[1] 李志坤[1] Zhao Yawei;Tang Lei;Li Qianyue;Ma Wang;Li Zhikun(Department of Urology Surgery,Xinjiang Production and Construction Corps Hospital,Urumqi 830002,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆生产建设兵团医院泌尿外科,乌鲁木齐830002

出　　处：《中国基层医药》2022年第5期683-687,共5页Chinese Journal of Primary Medicine and Pharmacy

基　　金：新疆生产建设兵团财政科技计划项目(2019AB033)。

摘　　要：目的探讨外周血循环肿瘤细胞(CTC)在前列腺癌诊治中的临床应用价值。方法选取新疆生产建设兵团医院2018年6月至2020年5月就诊的前列腺癌患者64例作为癌症组,同期入院的前列腺良性病变患者35例作为良性疾病组以及非前列腺疾病男性20例作为对照组。通过富集、分离、染色及识别CTC,并将其与Gleason评分和病理分期进行单因素方差分析。结果在癌症组、良性疾病组和对照组中CTC≥3的阳性率分别是73.43%(47/64)、17.14%(6/35)、10.00%(2/20)。CTC阳性组患者的前列腺特异抗原(PSA)水平明显高于CTC阴性组,差异有统计学意义(t=2.89,P<0.05)。CTC计数在各Gleason评分组(F=3.25,P<0.05)和病理分期组(F=3.42,P<0.05)比较,差异有统计学意义。结论外周血CTC检测可以作为前列腺疾病良恶性鉴别的辅助方法,前列腺癌患者CTC水平与PSA水平、Gleason评分及病理分期存在相关性,对预测患者的疾病预后有一定的辅助作用,具有一定的创新性和科学性。Objective To investigate the clinical value of peripheral blood circulating tumor cells(CTC)in the diagnosis and treatment of prostate cancer.Methods Sixty-four patients with prostate cancer who received treatment in Xinjiang Production and Construction Corps Hospital,China between June 2018 and May 2020 were included in the cancer group.An additional 35 patients with benign prostatic lesions who concurrently received treatment in the same hospital were included in the benign disease group.Twenty male patients with non-prostate disease were included in the control group.Cell enrichment,separation,staining and identification together with Gleason score and pathological stage were subjected to one-way analysis of variance.Results The percentage of patients with CTC count≥3 in the cancer,benign disease and control groups was 73.43%(47/64),17.14%(6/35)and 10.00%(2/20),respectively.The level of prostate-specific antigen in patients with CTC was significantly higher than that in patients without CTC(t=2.89,P<0.05).There was significant difference in CTC count between different Gleason score groups(F=3.25,P<0.05)and between different pathological stage groups(F=3.42,P<0.05).Conclusion Peripheral blood CTC measurement can be used as an auxiliary method for the differentiation of benign and malignant prostate diseases.CTC count in patients with prostate cancer is correlated with prostate-specific antigen level,Gleason score,and pathological stage.Therefore,peripheral blood CTC measurement plays an auxiliary role in predicting prognosis in patients with CTC.This study is innovative and scientific.

关 键 词：前列腺肿瘤 癌 肿瘤细胞 循环 前列腺特异抗原 肿瘤分期 早期诊断 预后 肿瘤标记 生物学 

分 类 号：R737.25[医药卫生—肿瘤]